Profile data is unavailable for this security.
About the company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-8.85m
- Incorporated2014
- Employees8.00
- LocationDermata Therapeutics Inc3525 Del Mar Heights Rd., #322SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 223-0882
- Fax+1 (302) 636-5454
- Websitehttps://www.dermatarx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oragenics Inc | 0.00 | -10.90m | 2.74m | 3.00 | -- | 0.2756 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 2.85m | 1.00 | -- | 0.1976 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.90m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 2.91m | 17.00 | -- | 0.4068 | -- | 0.8677 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 2.92m | 5.00 | -- | 0.1326 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 2.98m | 9.00 | -- | 0.9837 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 3.08m | 8.00 | -- | 0.2751 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Psyence Biomedical Ltd | -100.00bn | -100.00bn | 3.16m | 12.00 | -- | 0.0125 | -- | -- | -- | -- | -- | 247.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 101.98 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 3.17m | 5.00 | -- | 0.6032 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.21m | 0.00 | -- | 12.77 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.34m | 4.00 | -- | 0.1914 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Dermata Therapeutics Inc's reporting currency: US Dollar USD
3.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2025 | 81.65k | 2.88% |
| Clear Street LLCas of 31 Dec 2025 | 17.00k | 0.60% |
| Barclays Bank Plc (Private Banking)as of 31 Dec 2025 | 2.40k | 0.09% |
| UBS Securities LLCas of 31 Dec 2025 | 1.24k | 0.04% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2025 | 696.00 | 0.03% |
| Tower Research Capital LLCas of 30 Sep 2025 | 426.00 | 0.02% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 101.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 4.00 | 0.00% |
| Edward D. Jones & Co. LP (Investment Management)as of 30 Sep 2025 | 0.00 | 0.00% |
| XTX Markets LLCas of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
